LON:INDV - Indivior Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 111.70 +16.78 (+17.68 %) (As of 12/18/2018 01:47 PM ET)Previous CloseGBX 94.92Today's RangeGBX 91.12 - GBX 116.0552-Week RangeGBX 246.50 - GBX 436.60Volume9.01 million shsAverage Volume2.44 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in Richmond, Virginia. Receive INDV News and Ratings via Email Sign-up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drugs - Generic Sub-IndustryN/A SectorMedical Current SymbolLON:INDV Previous Symbol CUSIPN/A Webindivior.com Phone+44-1753-217800 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees900 Outstanding SharesN/AMarket Cap£0.00 OptionableNot Optionable Indivior (LON:INDV) Frequently Asked Questions What is Indivior's stock symbol? Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV." What price target have analysts set for INDV? 5 Wall Street analysts have issued 12-month price objectives for Indivior's shares. Their forecasts range from GBX 130 to GBX 398. On average, they anticipate Indivior's stock price to reach GBX 294.60 in the next year. This suggests a possible upside of 163.7% from the stock's current price. View Analyst Price Targets for Indivior. What is the consensus analysts' recommendation for Indivior? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Indivior. Has Indivior been receiving favorable news coverage? News articles about INDV stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Indivior earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the stock's share price in the near term. Who are some of Indivior's key competitors? Some companies that are related to Indivior include 22nd Century Group (XXII), 3D Signatures (DXD), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abaxis (ABAX), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acerus Pharmaceuticals (ASP), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Activecare (ACAR) and Advanced Accelerator Application (AAAP). Who are Indivior's key executives? Indivior's management team includes the folowing people: Mr. Shaun Thaxter, CEO & Exec. DirectorMr. Mark Crossley, CFO & Exec. DirectorDr. Christian Heidbreder, Chief Scientific OfficerMr. Ingo Elfering, Chief Information & Innovation OfficerMr. Jason Thompson, VP of Investor Relations How do I buy shares of Indivior? Shares of INDV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Indivior's stock price today? One share of INDV stock can currently be purchased for approximately GBX 111.70. What is Indivior's official website? The official website for Indivior is http://indivior.com/. How can I contact Indivior? Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company can be reached via phone at +44-1753-217800. MarketBeat Community Rating for Indivior (LON INDV)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 399 (Vote Outperform)Underperform Votes: 194 (Vote Underperform)Total Votes: 593MarketBeat's community ratings are surveys of what our community members think about Indivior and other stocks. Vote "Outperform" if you believe INDV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INDV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/18/2018 by MarketBeat.com StaffFeatured Article: Why do corrections happen?